Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written, documented consent to take part in the study.
• People whose general health and ability to carry out daily activities is rated at 0 or 1 on a standard medical scale (meaning fully active or able to do light work).
• People who have been confirmed by laboratory testing to have epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
• People who have previously received a standard first-line platinum-based chemotherapy treatment (given by drip or directly into the abdomen) after surgery, and whose cancer has since come back — maintenance treatment given after that first-line treatment counts as part of it.
• People whose cancer returned less than 12 months after their last platinum-based treatment ended, or less than 12 months after their last non-platinum treatment ended.
• People who have measurable cancer that can be detected and tracked using standard imaging criteria at the start of the study.
• People with a life expectancy of at least 12 weeks.
• People who are able to provide a tumour tissue sample, either from a previous surgery or a newly collected sample taken during the screening process.
• People who have adequate organ function as assessed by the trial site (confirm with trial site).
• People who have not yet fully recovered from side effects of a previous treatment to an acceptable level (confirm with trial site).

Who may not be able to join:

• People whose cancer is classified as non-epithelial, borderline, mucinous, predominantly mucinous seromucinous, malignant Brenner's tumour, or undifferentiated carcinoma.
• People who have previously received certain immunotherapy treatments that target specific immune system pathways, including PD-1, PD-L1, PD-L2, CTLA-4, OX-40, or CD137-directed therapies.
• People who have received any systemic cancer treatment, radiation, or maintenance therapy within 4 weeks before enrolling.
• People who have had a severe allergic reaction (Grade 3 or higher) or uncontrolled high blood pressure related to paclitaxel, nab-paclitaxel, pembrolizumab, or mirabegron, or any of their ingredients.
• People who have had major surgery within 3 weeks before enrolling, or who are still recovering from surgical complications.
• People who have had another cancer that was actively growing or being treated within the last 5 years.
• People who are pregnant or breastfeeding.
• People who have had an organ or tissue transplant from another person.
• People who have a history of blood clotting disorders, significant bleeding, coughing up blood, or active gastrointestinal bleeding within the 6 months before enrolling.
• People who have a history of an active autoimmune disease.
• People who currently have an active infection that requires treatment with systemic medication.
• People who have a history of HIV infection.
• People who have a history of Hepatitis B or Hepatitis C infection.
• People who have any other condition, treatment history, or abnormal test result that might affect the study results (confirm with trial site).
• People who have a known psychiatric condition or substance use disorder that could make it difficult to follow the study requirements.

Important: Always verify eligibility with the trial site directly before applying.